60 Degrees Pharmaceuticals, Inc. filed its Form 10-Q with the SEC on November 16, 2026, covering the quarterly period ended September 30, 2026, disclosing continued operating losses and a sharp decline in cash and total assets from year-end 2025.

Key Highlights

  • Cash position: Cash and cash equivalents fell to $306,191 as of September 30, 2026, down from $1,510,065 at December 31, 2025, according to the filing.
  • Total assets: Total assets declined to $3,094,102 as of September 30, 2026, compared with $5,366,211 at December 31, 2025.
  • Product revenues: Net product revenues for the nine months ended September 30, 2026 were $603,225, compared with $702,086 for the same period in 2025.
  • Accumulated deficit: The accumulated deficit reached $54,804,030 as of September 30, 2026, up from $47,893,115 at December 31, 2025.
  • Shares outstanding: Common shares issued and outstanding as of November 16, 2026 totaled 4,484,622, up from 1,163,142 at December 31, 2025.
  • Gross loss: The company reported a gross loss of $97,531 for the three months ended September 30, 2026, and gross profit of $35,644 for the nine months ended September 30, 2026.
  • Going concern: The filing's forward-looking statements reference the company's "ability to continue as a going concern and to obtain substantial additional financing in the near term" as a risk factor subject to uncertainty.

60 Degrees Pharmaceuticals Financial Position and Operations for the Quarter Ended September 30, 2026

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP), a Delaware-incorporated pharmaceutical company headquartered in Washington, D.C., filed its quarterly report covering the period ended September 30, 2026. According to the filing, total assets stood at $3,094,102 at the end of the quarter, a decrease of approximately $2.27 million from $5,366,211 reported at December 31, 2025. The company reported that cash and cash equivalents fell to $306,191 from $1,510,065 over the same span, and short-term investments, which were $1,240,721 at year-end 2025, reached zero by September 30, 2026.

On the revenue side, the filing disclosed net product revenues of $233,235 for the three months ended September 30, 2026, compared with $437,602 for the same quarter in 2025. For the nine-month period, net product revenues were $603,225 versus $702,086 in the prior-year period. Research revenues, which were $90,960 and $390,630 for the three- and nine-month periods ending September 30, 2025, respectively, were reported as zero for both comparable 2026 periods. Cost of revenues for the three months ended September 30, 2026 was $330,766, resulting in a gross loss of $97,531 for the quarter.

The company's accumulated deficit grew to $54,804,030 as of September 30, 2026, from $47,893,115 at December 31, 2025. Total shareholders' equity was reported at $755,911, down from $3,379,416 at year-end 2025. Common stock shares issued and outstanding increased significantly, from 1,163,142 at December 31, 2025 to 3,900,130 at September 30, 2026, and further to 4,484,622 as of November 16, 2026, as reported on the cover page of the filing. Series A Preferred Stock shares outstanding declined to 68,080 from 76,480 over the same period. The filing notes that forward-looking statements, including those regarding going concern and financing, are subject to the company's cautionary language and risks described within the report.

What Was Disclosed

60 Degrees Pharmaceuticals filed its 10-Q for the quarter ended September 30, 2026, disclosing a decline in cash, total assets, and product revenues compared with prior periods, alongside a growing accumulated deficit and a substantially higher common share count.